Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-005277-27 | EudraCT Number | ||
| 64300535HPB1003 | Other Identifier | Janssen Research & Development, LLC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the cellular immunogenicity of 3 monthly electroporation-mediated intramuscular (IM) injections of JNJ-64300535 in healthy participants.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| JNJ-64300535 | Experimental | Participants will receive an electroporation-mediated intramuscular (IM) injection of JNJ-64300535 vaccine. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| JNJ-64300535 | Biological | JNJ-64300535 injection will be administered intramuscularly. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Responding Against Hepatitis B Virus (HBV) Core or Polymerase (Pol) Vaccine Antigens | Percentage of participants responding against HBV Core or Pol vaccine antigens will be reported. | Up to Day 67 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Solicited Local Adverse Events (AEs) | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs are pre-defined local (at the injection site) AEs for which participants will be specifically questioned and which will be noted by participants in their diary for 7 days post first vaccination. Solicited local AEs are: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| SGS Belgium NV | Edegem | 2650 | Belgium |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41644953 | Derived | Verheijden S, Conceicao-Neto N, Bourgeois S, Vandamme C, Troyer E, Kanoulas E, Maeyer D, Crabbe M, Makariadou E, Slaets L, Fevery B, Remoortere PV, Biermer M, Kennedy PTF, De Creus A. Safety, immunogenicity, and baseline immune correlates of vaccine JNJ-0535 in participants with or without CHB. NPJ Vaccines. 2026 Feb 5;11(1):45. doi: 10.1038/s41541-025-01364-x. |
Not provided
Not provided
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to Day 64 |
| Number of Participants With Solicited Systematic Adverse Events | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Participants will be instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events will include fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills. | Up to Day 64 |
| Number of Participants With Serious Adverse Events (SAEs) | A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Number of participants with SAEs will be reported. | Up to Day 225 |
| Number of Participants With Unsolicited Adverse Events | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Unsolicited AEs are events which will be reported by the participant voluntarily or obtained by means of interviewing the participant in a non-directed manner at study visits. | Up to Day 225 |
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | Number of participants with clinically significant abnormalities in laboratory parameters such as (hematology, blood biochemistry, blood coagulation and urinalysis) will be reported. | Up to Day 225 |
| Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) | Number of participants with clinically significant abnormalities in ECG will be reported. | Up to Day 113 |
| Number of Participants With Clinically Significant Abnormalities in Vital Signs | Number of participants with clinically significant abnormalities in vital signs (including body temperature, pulse/heart rate, systolic and diastolic blood pressure) will be reported. | Up to Day 225 |
| Number of Participants With Clinically Significant Abnormalities in Physical Examination | Number of participants with clinically significant abnormalities in physical examination (including height, body weight, skin examination, and other body systems) will be reported. | Up to Day 225 |
| Percentage of Participants With a Positive T-cell Response Against HBV Core or Pol Vaccine Antigens | Percentage of participants with a positive T-cell response against HBV Core or Pol vaccine antigens will be reported. | Up to Day 225 |
| Breadth of the T-cell Responses Against HBV Core or Pol Vaccine Antigens | Breadth of the T-cell responses against HBV Core or Pol vaccine antigens will be reported. | Up to Day 225 |
| Magnitude of the T-cell Responses Against HBV Core or Pol Vaccine Antigens | Magnitude of the T-cell responses against HBV Core or Pol vaccine antigens will be reported | Up to Day 225 |
| Number of Cytokines of Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) T-cell Responses Against HBV Core or Pol Vaccine Antigens | Number of cytokines of both CD4 and CD8 T-cell responses against HBV Core or Pol vaccine antigens will be reported. | Up to Day 225 |
| Frequency of Intramuscular TriGrid Delivery System version 2.0 (TDS-IM v2.0) Device Faulty Conditions | Frequency of device fault conditions observed during administration of study treatment with TDS-IM v2.0 device will be reported. | Up to Day 57 |